Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUNING plus peramivir for treatment of human H7N9 avian influenza
ChiCTR-IPR-15006047Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Feb 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Reduning in avian influenza A H7N9 (A(H7N9)) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Time to temperature normalization, Clinical symptom improvement rate and 7 more. Started Feb 2015; status: recruiting.
02
Drugs
Reduning
03
Conditions
avian influenza A H7N9 (A(H7N9))
Beyond the preview
Go deeper on ChiCTR-IPR-15006047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006047.